Evidence map›Paper›PMID 41721205›Full record

ReviewCNS neuroscience & therapeutics2026

From Regeneration Failure to Functional Restoration: Unlocking the Neuronal-Intrinsic Regenerative Capacity as a Therapeutic Frontier for Optic Neuropathy and Glaucoma.

Emma Beard, Safa El-Bushra, Zahra Kader, Yujiao Jennifer Sun, Ngan Pan Bennett Au

Abstract readReview
In one paragraph

Review in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emma BeardSchool of Medicine, Pharmacy and Biomedical Science, Faculty of Science and Health, University of Portsmouth, Portsmouth, UK.ORCID https://orcid.org/0009-0009-2845-1915
Safa El-BushraSchool of Medicine, Pharmacy and Biomedical Science, Faculty of Science and Health, University of Portsmouth, Portsmouth, UK.
Zahra KaderUCL Institute of Ophthalmology, London, UK.ORCID https://orcid.org/0009-0004-2534-7884
Yujiao Jennifer SunUCL Institute of Ophthalmology, London, UK.ORCID https://orcid.org/0000-0003-2437-2936
Ngan Pan Bennett AuDepartment of Comparative Biomedical Sciences, School of Veterinary Medicine, University of Surrey, Guildford, UK.ORCID https://orcid.org/0000-0003-0245-9096

Funding

Fight for Sight/Glaucoma UK RESSGA2510Moorfields Eye Charity (MEC) Springboard Award GR001652Rosetrees/Stoneygate Trust Seedcorn2024/100044Royal Society Project Grant RG/R1/251126Sight Research UK SEE037_Au_University of Surrey
6 · The paper itself

Abstract

backgroundOptic neuropathy encompasses ocular conditions arising from traumatic or nontraumatic damage to optic nerves, causing permanent visual impairment due to retinal ganglion cell (RGC) loss and disrupted axonal connections. Glaucomatous optic neuropathy represents the most prevalent form, affecting over 70 million individuals worldwide and causing blindness in nearly 4 million people. CURRENT LIMITATIONS: Current treatments targeting elevated intraocular pressure can slow disease progression but cannot restore vision once RGC axons are lost, largely due to regeneration failure in surviving RGCs. This regenerative failure stems not merely from the presence of growth-inhibitory extrinsic factors, but crucially from diminished neuronal-intrinsic regenerative capacity in mature RGCs. MECHANISTIC INSIGHTS AND THERAPEUTIC IMPLICATIONS: This review explores how intrinsic growth barriers and inadequate activation of pro-regenerative genes impede axonal regrowth following injury, and how manipulations of these pathways facilitate axon regeneration and visual recovery in experimental models. Emerging findings suggest that these pro-regenerative molecules capable of modifying the neuronal-intrinsic regenerative capacity of RGCs can also preserve visual function in pre-clinical glaucoma models. Finally, we discuss challenges and future directions for translating these findings into therapies, including gene delivery strategies, remyelination therapeutics, and systems biology-based in silico drug screening approaches aiming to reshape the therapeutic landscape towards regenerative interventions for glaucomatous and other optic neuropathies.

Indexed as

GlaucomaNerve RegenerationOptic Nerve DiseasesRecovery of FunctionAnimalsAxonsHumansRetinal Ganglion Cellsglaucomamitochondria‐targeted therapyoptic nerve injuryoptic neuropathyregenerative medicinesmall molecules‐based treatment

Identifiers

PMID41721205
PMCPMC12928094

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.